These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 10096572)

  • 21. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
    FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells.
    Shima Y; Nakao K; Nakashima T; Kawakami A; Nakata K; Hamasaki K; Kato Y; Eguchi K; Ishii N
    Hepatology; 1999 Nov; 30(5):1215-22. PubMed ID: 10534343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
    Mincione G; Di Marcantonio MC; Artese L; Vianale G; Piccirelli A; Piccirilli M; Perrotti V; Rubini C; Piattelli A; Muraro R
    Int J Oncol; 2008 Feb; 32(2):323-31. PubMed ID: 18202754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2.
    Sheng H; Shao J; O'Mahony CA; Lamps L; Albo D; Isakson PC; Berger DH; DuBois RN; Beauchamp RD
    Oncogene; 1999 Jan; 18(4):855-67. PubMed ID: 10023661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation.
    Winter RN; Rhee JG; Kyprianou N
    Anticancer Res; 2004; 24(3a):1377-86. PubMed ID: 15274298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
    Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
    Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X; Bellis S; Yan Z; Friedman E
    Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
    Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
    Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
    Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
    Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M; Oyasu R
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
    Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
    Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro.
    Zhao Y; Peng J; Zheng L; Yu W; Jin J
    Prostate; 2010 Jun; 70(8):899-905. PubMed ID: 20135646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
    Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
    Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation.
    Jakowlew SB; Moody TW; Mariano JM
    Anticancer Res; 1997; 17(3C):1849-60. PubMed ID: 9216635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.